Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The said drug is equivalent to reference listed drug, Bridion injection.

The pharma company said that the injection will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara.

According to IQVIA MAT August 2023, Sugammadex injection, singledose vial had annual sales of $986 million in the United States.

As of 30 June 2023, the group has 381 approvals and has so far filed over 444 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company had reported 109.7% surge in net profit to Rs 1,086.9 crore in Q1 FY24 as compared with Rs 518.3 crore posted in Q1 FY23. Revenue from operations jumped 29.6% to Rs 5,139.6 crore during the quarter as compared with Rs 3,964.4 crore recorded in same quarter last year.

Shares of Zydus Lifesciences were down 0.25% to Rs 603.15 on the BSE.